Biopharma confidence hits four-year high as firms restructure, invest in R&D

M&A deals' value rose 71% YoY in Q1.

Confidence in the biopharmaceutical industry has climbed to its highest level since 2022, with 55% of surveyed stakeholders optimistic about the industry’s growth over the next 12 months.

According to GlobalData, this reflects the impact of strategic restructuring, disciplined capital allocation, and renewed investment in innovation.

The report also noted that companies have restructured cost bases, developed priorities, and engaged directly with policymakers rather than waiting for certainty.

In the first quarter of the year, the value of mergers and acquisitions deals rose 71% year over year, and the Initial Public Offering market has reopened sharply, with activity up 210%.

“The science in cardiometabolic, oncology, and neurology is genuinely compelling right now, and the market is pricing that in,” Hannah Hans, head of pharma strategic intelligence at GlobalData, said.

However, headwinds such as the United States’ tariffs and government actions were pointed out by 69% as the biggest policy concern facing the industry.